One of Europe’s largest dentistry providers
+7.5% of incremental EBITDA through price optimisation
Guide in effective price change communication
A roadmap for the future
A roadmap with 11 prioritised and sequenced opportunities, totalling 20-40% in EBITDA upside
Market research provided a foundational base by identifying where the ‘affordable price range’ lies.
The research provided insights by treatment-type and allowed understanding of patient behaviours, decision making processes and the role of price.
Identified competitor price positioning across a range of corporate and independent clinics, to inform strategy within different localities.
Evaluated performance drivers and revenue levers at a transaction level.
Thorough insights generated, enabling the building of a pricing fact base, and unlocking crucial insights to inform the price optimisation process.
Data-driven process that collated insights from customer, competitors and transaction analysis to arrive at optimal price points at a treatment level.
Taken was a highly collaborative approach where price recommendations were workshopped to align on approach and ensure all nuance was captured.
Held a workshop with the client to present and discuss further opportunities to drive growth over the short, medium and long term.
The roadmap discussed included opportunities for EBITDA growth on +20% to +40% over time.
Complete this form to get in touch with our Healthcare & Life Sciences lead, Emil Risom Foged.